coin-img-BTCBTC-1.12%coin-img-SOLSOL-0.81%coin-img-USDCUSDC+0.00%coin-img-ULTIMAULTIMA+23.35%coin-img-UBOXUBOX-63.95%coin-img-XRPXRP-0.77%coin-img-HYPEHYPE-4.93%coin-img-ETHETH-0.90%coin-img-BTCBTC-1.12%coin-img-SOLSOL-0.81%coin-img-USDCUSDC+0.00%coin-img-ULTIMAULTIMA+23.35%coin-img-UBOXUBOX-63.95%coin-img-XRPXRP-0.77%coin-img-HYPEHYPE-4.93%coin-img-ETHETH-0.90%coin-img-BTCBTC-1.12%coin-img-SOLSOL-0.81%coin-img-USDCUSDC+0.00%coin-img-ULTIMAULTIMA+23.35%coin-img-UBOXUBOX-63.95%coin-img-XRPXRP-0.77%coin-img-HYPEHYPE-4.93%coin-img-ETHETH-0.90%coin-img-BTCBTC-1.12%coin-img-SOLSOL-0.81%coin-img-USDCUSDC+0.00%coin-img-ULTIMAULTIMA+23.35%coin-img-UBOXUBOX-63.95%coin-img-XRPXRP-0.77%coin-img-HYPEHYPE-4.93%coin-img-ETHETH-0.90%
user-avatar
scanx.trade

SMS Pharmaceuticals Q1 net profit rises 16% YoY to ₹20.9 crore

AI Market Summary
SMS Pharmaceuticals reported Q1FY27 consolidated net profit of ₹20.90 crore, up 16% YoY, while revenue was broadly flat, pointing to efficiency gains but limited demand expansion. The board also approved reappointing the Chairman & Managing Director and proposed an unsecured loan of up to ₹50 crore to its near wholly owned subsidiary, subject to shareholder approval. Overall implications are company specific with limited broader market spillover.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.15%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
SMS Pharmaceuticals posted Q1 FY2027 results for the quarter ended June 30, 2026, with consolidated net profit at ₹20.90 crore, up 16% year on year. Standalone net profit was ₹21.13 crore, also up 16%. Basic and diluted earnings per share were ₹2.23. The board approved the reappointment of Ramesh Babu Potluri as Chairman and Managing Director for five years from October 1, 2026, to September 30, 2031, subject to shareholder approval, and the company holds 99.99% of its subsidiary.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.